| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria |
|
Medicine details |
|
| Medicine name | ravulizumab (Ultomiris®) |
| Formulation | 300 mg concentrate for solution for infusion |
| Reference number | 3495 |
| Indication | Treatment of adult patients with paroxysmal nocturnal haemoglobinuria: in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months |
| Company | Alexion Pharma UK Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/07/2020 |
| NICE guidance | TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria |